United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
487.61
-2.63 (-0.54%)
Sep 4, 2026, 4:00 PM EDT - Market closed

United Therapeutics Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, United Therapeutics stock has a consensus rating of "Buy" and an average price target of $664.33. The average 1-year stock price forecast is 36.24% higher than the current stock price, while the lowest is $515 (+5.62%) and the highest is $725 (+48.68%).

Price Target: $664.33 (+36.24%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$515$664.33$685$725
Change+5.62%+36.24%+40.48%+48.68%

Analyst Ratings

The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy999998
Buy123333
Hold443333
Sell000000
Strong Sell000000
Total141515151514

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Wells Fargo
Wells Fargo
Buy
Maintains
$700
BuyMaintains$700+43.56%Sep 2, 2026
TD Cowen
TD Cowen
Buy
Maintains
$675
BuyMaintains$675+38.43%Sep 2, 2026
RBC Capital
RBC Capital
Buy
Maintains
$677
BuyMaintains$677+38.84%Aug 25, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$660
BuyMaintains$660+35.35%Aug 6, 2026
Morgan Stanley
Morgan Stanley
Hold
Reiterates
$516$515
HoldReiterates$516$515+5.62%Aug 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
3.14B
from 3.18B
Decreased by -1.36%
Revenue Next Year
3.44B
from 3.14B
Increased by 9.63%
EPS This Year
27.57
from 27.86
Decreased by -1.03%
EPS Next Year
30.03
from 27.57
Increased by 8.92%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.69B1.94B2.33B2.88B3.18B3.14B
Revenue Growth
13.63%14.88%20.20%23.63%10.61%-1.36%
Gross Profit
1.56B1.78B2.07B2.57B2.80B2.72B
Gross Margin
92.73%92.17%88.94%89.24%87.92%86.50%
Operating Income
686.90M989.00M1.19B1.45B1.52B1.36B
Net Income
475.80M727.30M984.80M1.20B1.33B1.20B
EPS
----27.8627.57
EPS Growth
----13.07%-1.03%
Forward PE
13.4513.579.9312.1717.1417.68
Free Cash Flow
406.69M506.28M613.49M834.08M583.20M1.23B
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High3.2B
Avg3.1B
Low3.0B

Revenue Growth

Revenue Growth202620272028
High
0.8%
Avg
-1.4%
Low
-4.3%

EPS Forecast

EPS202620272028
High29.05
Avg27.57
Low26.23

EPS Growth

EPS Growth202620272028
High
4.3%
Avg
-1.0%
Low
-5.9%